Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ConvaTec ( (GB:CTEC) ) has provided an update.
Convatec has disclosed that conditional share awards granted in 2023 to chief executive Jonny Mason and chief financial officer Fiona Ryder under its Long Term Incentive Plan and Deferred Bonus Plan vested on 15 March 2026 and were released on 16 March. After selling a portion of the newly vested shares at £2.344 to meet income tax and National Insurance liabilities, both executives retained significant shareholdings, underscoring ongoing equity-based alignment between senior management and shareholders.
The transactions, conducted partly outside a trading venue and partly on the London Stock Exchange, increase direct equity exposure for the CEO and CFO through performance share awards and restricted stock units. The disclosure, made under market abuse regulations, highlights Convatec’s continued use of long-term share incentives as a key element of executive remuneration, reinforcing governance transparency and tying leadership rewards to the company’s long-term performance.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on CTEC Stock
According to Spark, TipRanks’ AI Analyst, CTEC is a Neutral.
The score is driven primarily by solid underlying financial performance (growth, improving operating margins, positive free cash flow) and supportive guidance for continued growth and margin expansion. This is tempered by increased leverage and notable operational/regulatory risks flagged on the call, while valuation looks expensive and technicals appear near overbought despite an uptrend.
To see Spark’s full report on CTEC stock, click here.
More about ConvaTec
Convatec Group Plc is a global medical products and technologies company focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. The FTSE 100 constituent operates in around 90 countries, employs over 10,000 people and generated more than $2 billion in revenue in 2025.
Average Trading Volume: 8,286,107
Technical Sentiment Signal: Strong Buy
Current Market Cap: £4.56B
See more insights into CTEC stock on TipRanks’ Stock Analysis page.